Evidence map›Paper›PMID 37330481›Full record

ArticleBMC bioinformatics2023

Exploration of m

Weiwei Qian, Jian Zhou, Songtao Shou

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. mFrontiers in immunology · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. IGFBP-2 in Critical Illness: A Prognostic Marker in the Growth Hormone/Insulin-like Growth Factor Axis.Pathophysiology : the official journal of the International Society for Pathophysiology · 2024
    Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Weiwei Qian *Tianjin Medical University, Tianjin, 300203, China.
Jian Zhou *Department of Immunology, International Cancer Center, Shenzhen University Health Science Center, Shenzhen, 518060, China.
Songtao ShouDepartment of Emergency, Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, Tianjin, 300052, China. zyyshou@tmu.edu.cn.
Shenzhen University Health Science Center · CNTianjin Medical University General Hospital · CNWest China Hospital of Sichuan University · CN

Funding

GuangDong Basic and Applied Basic Research Foundation 2022A1515111162
6 · The paper itself

Abstract

backgroundThis study aims to deeply explore the relationship between m

methodsA single cell expression dataset of peripheral immune cells containing blood samples from 4 patients with advanced sepsis and 5 healthy subjects was obtained from the gene expression comprehensive database (GSE175453). Differential expression analysis and cluster analysis were performed on 21 m

resultsIGFBP1, IGFBP2, IGF2BP1, and WTAP were highly expressed in patients with advanced sepsis and m

conclusionIGFBP1, IGFBP2, IGF2BP1, WTAP, and METTL16 may accelerate the development of advanced sepsis by regulating m

Indexed as

ImmunotherapySepsisCluster AnalysisEpigenesis, GeneticHumansMethylationMethyltransferasesMethyltransferasesMETTL16 protein, humanAdvanced sepsisImmunoregulationm6A methylation modification

Identifiers

PMID37330481
PMCPMC10276409
OpenAlexW4381094233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.